| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
5 companies
Venrock Healthcare Capital Partners III, L.P. is 10% Owner at LYCA, with reported holdings spanning 5 companies.
Our model assigns Venrock Healthcare Capital Partners III, L.P. a middling insider score of 54/100, based on 37 past trades. Over a 12-month horizon, 37.8% of those trades were profitable, with an average 12-month return of +9.6%.
Venrock Healthcare Capital Partners III, L.P.'s largest disclosed position is in ORKA as 10% Owner, worth about $413.0M. Net of sales, the ORKA filings show accumulation of 122,882 shares.
Venrock Healthcare Capital Partners III, L.P. has 21 Form 4 filings on record from May 2020 to October 2026, across 5 companies: 10% Owner at Lycia Therapeutics (LYCA), 2026; 10% Owner at KalVista Pharmaceuticals (KALV), 2023–2025; 10% Owner at Oruka Therapeutics (ORKA), 2025, and 2 more.
The 62 reported transactions were 59 open-market purchases, 2 other transactions and 1 conversion.
Counted by filing, the open-market trades come to 19 purchases worth about $83.0M and no sales.
The largest open-market purchase was 2,045,440 shares of LYCA at an average $18.41 on October 27, 2026, about $37.7M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | LYCA Lycia Therapeutics, Inc. | 10% Owner | Buy | 25,004 | $25.78 | $644,711.28 | +0.4% | - | - | |
| Oct 27, 2026 | LYCA Lycia Therapeutics, Inc. | 10% Owner | Buy | 2,045,440 | $18.41 | $37,653,863.30 | +42.8% | - | - | |
| Apr 9, 2025 | KALV Kalvista Pharmaceuticals, Inc. | 10% Owner | Buy | 25,000 | $9.42 | $235,500.00 | +0.5% | +38.2% | +84.4% | |
| Feb 14, 2025 | ORKA Oruka Therapeutics, Inc. | 10% Owner | Buy | 122,882 | $11.45 | $1,407,367.87 | +3.1% | -15.4% | +188.1% | |
| Feb 13, 2025 | KALV Kalvista Pharmaceuticals, Inc. | 10% Owner | Buy | 161,700 | $9.27 | $1,498,661.00 | +3.2% | +19.0% | +56.5% | |
| Feb 11, 2025 | KALV Kalvista Pharmaceuticals, Inc. | 10% Owner | Buy | 104,489 | $9.26 | $967,144.93 | +2.1% | +31.4% | +67.3% | |
| Feb 3, 2025 | KALV Kalvista Pharmaceuticals, Inc. | 10% Owner | Buy | 70,023 | $8.88 | $621,628.02 | +1.4% | +42.1% | +74.9% | |
| Feb 8, 2024 | KALV Kalvista Pharmaceuticals, Inc. | 10% Owner | Buy | 86,048 | $14.62 | $1,257,828.78 | +1.8% | -19.1% | -38.3% | |
| Jan 30, 2024 | KALV Kalvista Pharmaceuticals, Inc. | 10% Owner | Buy | 88,099 | $14.47 | $1,274,792.53 | +1.9% | -25.7% | -40.8% | |
| Jan 29, 2024 | KALV Kalvista Pharmaceuticals, Inc. | 10% Owner | Buy | 91,804 | $14.05 | $1,289,802.42 | +2.0% | -23.2% | -38.1% |